



Pharma Industry has increased R&D investments




Investments are expected to increase in the coming two years



Pharma companies expect to invest approximately 32 millions more to Finland in coming two years.


Number of trials and patients in Finland 2018



In Finland most of the clinical trials are conducted with cancer medicines but the most of the patients are in cardio-vascular trials.


Number of trials and patients in 2018

medicine and vaccine studies




There were 191 medicine and vaccine studies, in which approximately 7 500 patients participated in Finland in 2018.

Clinical trials in the most significant ATC-groups in Finland in 2018




Source: Pharma Industry Finland 2019

Trial subjects in different indication areas without vaccine studies in Finland in 2018




The number of clinical trial notified to Fimea



Source: Fimea 2019

How the number of registry studies is going change in the coming two years



Registry studies are typically based on health registries or other national registries. The studies are based on large samples and big data sets. Typically one cannot identify trial subjects in the data. The studies might be a request of authorities or company need to follow the actual use of their products.